Market Place
Sourcing Support
Cara Therapeutics and Tvardi Enter Merger Agreement
18 Dec 2024 //
GLOBENEWSWIRE
Cara Therapeutics Announces Exploration of Strategic Alternatives
11 Jul 2024 //
GLOBENEWSWIRE
Cara Therapeutics discontinues neurological condition study as drug fails
13 Jun 2024 //
REUTERS
Cara Therapeutics Announces Outcome Of KOURAGE-1 Study Part A
12 Jun 2024 //
GLOBENEWSWIRE
Cara Therapeutics Reports First Quarter 2024 Financial Results
13 May 2024 //
GLOBENEWSWIRE
Cara To Announce Q1 2024 Results On May 13
06 May 2024 //
GLOBENEWSWIRE
Oruka Expands Leadership, Appoints Joana Goncalves as CMO
24 Apr 2024 //
GLOBENEWSWIRE
Cara Thera to Present at the 23rd Annual Needham Virtual Healthcare Conference
02 Apr 2024 //
GLOBENEWSWIRE
Cara Therapeutics to Host NP Virtual KOL Event on Wednesday, March 27, 2024
07 Mar 2024 //
GLOBENEWSWIRE
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
04 Mar 2024 //
GLOBENEWSWIRE
Cara Therapeutics to Announce Fourth Quarter & Full Year 2023 Financial Results
12 Feb 2024 //
GLOBENEWSWIRE
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program
22 Jan 2024 //
GLOBENEWSWIRE
Itch treater Cara cuts 50% of team to extend runway into 2026
22 Jan 2024 //
FIERCE BIOTECH
Cara Announces Outcome from Dose-Finding Part A of Evaluating Difelikefalin
18 Dec 2023 //
GLOBENEWSWIRE
Cara Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Cara Therapeutics Announces up to $40.0 Million
02 Nov 2023 //
GLOBENEWSWIRE
Cara Therapeutics to Announce Third Quarter 2023 Financial Results
23 Oct 2023 //
GLOBENEWSWIRE
Cara Announces Approval of KORSUVA® IV Injection Syringe in Japan
25 Sep 2023 //
GLOBENEWSWIRE
Cara Therapeutics Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
03 Aug 2023 //
GLOBENEWSWIRE
Cara Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
02 Aug 2023 //
GLOBENEWSWIRE
Cara Therapeutics to Announce Q2 2023 Financial Results on August 7, 2023
24 Jul 2023 //
GLOBENEWSWIRE
Cara Therapeutics to Present at the Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
Kapruvi (difelikefalin) recommended by England NICE
18 May 2023 //
GLOBENEWSWIRE
Cara Therapeutics Reports First Quarter 2023 Financial Results
15 May 2023 //
GLOBENEWSWIRE
Cara Therapeutics to Announce 1Q 2023 Financial Results on May 15, 2023
01 May 2023 //
GLOBENEWSWIRE
Cara Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference
10 Apr 2023 //
GLOBENEWSWIRE
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
06 Mar 2023 //
GLOBENEWSWIRE
Cara Therapeutics to Announce Q4 and Full Year 2022 Financial Results on March 6
21 Feb 2023 //
GLOBENEWSWIRE
Cara Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin
08 Feb 2023 //
GLOBENEWSWIRE
Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
17 Jan 2023 //
GLOBENEWSWIRE
Cara Therapeutics Presentation at the 41st Annual J.P. Morgan Conference
03 Jan 2023 //
GLOBENEWSWIRE
Cara Therapeutics Reports Third Quarter 2022 Financial Results
07 Nov 2022 //
GLOBENEWSWIRE
Cara Announces Appointment of Lisa von Moltke to its Board of Directors
03 Nov 2022 //
GLOBENEWSWIRE
Cara Therapeutics to Present at Upcoming Investor Conferences
02 Nov 2022 //
GLOBENEWSWIRE
Cara Therapeutics to Announce Third Quarter 2022 Financial Results
24 Oct 2022 //
GLOBENEWSWIRE
Cara Therapeutics Announces Difelikefalin (KORSUVA®) InjectionNDA
28 Sep 2022 //
GLOBENEWSWIRE
Cara`s Presents Late-Breaking Results Ph 2 Trial of Oral Difelikefalin
08 Sep 2022 //
GLOBENEWSWIRE
Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on Sep 20, 2022
24 Aug 2022 //
GLOBENEWSWIRE
Cara Announces KOMFORT Data Accepted for Late-Breaking Presentation
22 Aug 2022 //
GLOBENEWSWIRE
Kapruvia approved in Switzerland with additional regulatory decisions
19 Aug 2022 //
GLOBENEWSWIRE
Cara Therapeutics Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Cara Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
03 Aug 2022 //
GLOBENEWSWIRE
Cara Therapeutics to Announce Second Quarter 2022 Financial Results
01 Aug 2022 //
GLOBENEWSWIRE
9 Meters and Cara tout mid-stage data for gastrointestinal, pruritus studies
30 Jun 2022 //
ENDPTS
Cara Tx`s Positive Topline Results from KOMFORT PII Trial of Oral Difelikefalin
30 Jun 2022 //
GLOBENEWSWIRE
Cara Therapeutics to Present at Upcoming Investor Conferences
17 May 2022 //
GLOBENEWSWIRE
Cara Therapeutics Reports First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Cara Therapeutics to Present at May Investor Conferences
03 May 2022 //
GLOBENEWSWIRE
Cara Therapeutics to Announce Q1 2022 Financial Results on May 9, 2022
29 Apr 2022 //
GLOBENEWSWIRE
Kapruvia approved by EC for moderate-to-severe pruritus in hemodialysis
28 Apr 2022 //
BUSINESSWIRE
Cara Therapeutics to Present at Needham Virtual Healthcare Conference
05 Apr 2022 //
GLOBENEWSWIRE
Cara Therapeutics Shows Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA
04 Apr 2022 //
GLOBENEWSWIRE
Cara Tx Announces Oral KORSUVA Shows Improvement in Atopic Dermatitis
28 Mar 2022 //
PRESS RELEASE
Cara Tx says Oral KORSUVA Data Selected for AACR
08 Mar 2022 //
GLOBENEWSWIRE
Cara Tx Reports Q4 and Full Year 2021 Financial Results
01 Mar 2022 //
GLOBENEWSWIRE
Kapruvia receives positive CHMP opinion for pruritus in hemodialysis patients
28 Feb 2022 //
BUSINESSWIRE
Cara Tx to Announce Q4 and Full Year 2021 Financial Results on March 1
22 Feb 2022 //
GLOBENEWSWIRE
Cara Therapeutics to Host Virtual R&D Day on March 11, 2022
18 Feb 2022 //
GLOBENEWSWIRE
Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™
20 Dec 2021 //
GLOBENEWSWIRE
